Advertisement

Efficacy of Ivabradine, a Selective If Inhibitor, in Patients With Chronic Stable Angina Pectoris and Diabetes Mellitus

Published:November 09, 2009DOI:https://doi.org/10.1016/j.amjcard.2009.08.642
      Ivabradine is a specific heart rate-lowering antianginal agent that was evaluated in a clinical development program involving approximately 3,000 patients with stable coronary artery disease, most with angina pectoris. We analyzed the pharmacokinetics, efficacy (evaluated by exercise tolerance testing), safety, and effects on glucose metabolism of ivabradine in patients with diabetes mellitus (DM) in this program. Most analyses included data from 535 patients with DM, approximately 18% of the overall patient sample. Patients with DM were older, more likely to be women, and more likely to have more severe angina pectoris than patients without DM. The pharmacokinetics of ivabradine did not differ in patients with DM versus those without DM. A reduction in the heart rate at rest with ivabradine was similar in those with (15.2%) and without (15.7%) DM. At baseline, the exercise capacity tended to be lower in the patients with DM, but the improvements in most exercise tolerance measures with ivabradine treatment were similar in patients with and without DM. No special safety concerns were associated with ivabradine in those with DM. The rates of sinus bradycardia and visual disturbances, known to be related to the action of ivabradine, showed no relative increase in the patients with DM. Ivabradine treatment was not associated with adverse effects on glucose metabolism. In conclusion, ivabradine was effective in preventing angina in patients with DM and was not associated with particular safety concerns or adverse effects on glucose metabolism. Ivabradine represents an attractive alternative to β blockers in patients with stable angina pectoris and DM.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • DiFrancesco D.
        Funny channels in the control of cardiac rhythm and mode of action of selective blockers.
        Pharmacol Rev. 2006; 53: 399-406
        • Camm A.J.
        • Lau C.P.
        Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology.
        Drugs R D. 2003; 4: 83-89
        • Manz M.
        • Reuter M.
        • Lauck G.
        • Omran H.
        • Jung W.
        A single dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction.
        Cardiology. 2003; 100: 149-155
        • Joannides R.
        • Moore N.
        • Iacob M.
        • Compagnon P.
        • Lerebours G.
        • Menard J.F.
        • Thuillez C.
        Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise.
        Br J Clin Pharmacol. 2006; 61: 127-137
        • Borer J.S.
        • Fox K.
        • Jaillon P.
        • Lerebours G.
        Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial.
        Circulation. 2003; 107: 817-823
        • Tardif J.-C.
        • Ford I.
        • Tendera M.
        • Bourassa M.G.
        • Fox K.
        • INITIATIVE Investigators
        Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina.
        Eur Heart J. 2005; 26: 2529-2536
        • Ruzyllo W.
        • Tendera M.
        • Ford I.
        • Fox K.M.
        Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.
        Drugs. 2007; 67: 393-405
        • Fox K.
        • Garcia M.A.
        • Ardessino D.
        • Buszman P.
        • Camici P.G.
        • Crea F.
        • Daly C.
        • De Backer G.
        • Hjemdahl P.
        • Lopez-Sendon J.
        • Marco J.
        • Morais J.
        • Pepper J.
        • Sechtem U.
        • Simoons M.
        • Thygesen K.
        • The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology
        Guidelines on the management of stable angina pectoris: executive summary.
        Eur Heart J. 2006; 27: 1341-1381
        • Fox K.
        • Ford I.
        • Steg P.G.
        • Tendera M.
        • Ferrari M.
        • BEAUTIFUL Investigators
        Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial.
        Lancet. 2008; 372: 807-816
        • Tardif J.C.
        • Ponikowski P.
        • Kahan T.
        • ASSOCIATE study investigators
        Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial.
        Eur Heart J. 2009; 30: 540-548
        • Cowie C.C.
        • Rust K.F.
        • Byrd-Holt D.D.
        • Eberhardt M.S.
        • Fiegal K.M.
        • Engelgau M.M.
        • Saydah S.H.
        • Williams D.E.
        • Geiss L.S.
        • Gregg E.W.
        Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999–2002.
        Diabetes Care. 2006; 29: 1263-1268
        • Narayan K.M.
        • Boyle J.P.
        • Geiss L.S.
        • Saadine J.B.
        • Thompson T.J.
        Impact of recent increase in incidence on future diabetes burden: U.A., 2005–2050.
        Diabetes Care. 2006; 29: 2114-2116
        • Vinik A.I.
        • Maser R.E.
        • Mitchell B.D.
        • Freeman R.
        Diabetic autonomic neuropathy.
        Diabetes Care. 2003; 26: 1553-1579
        • Schroeder E.B.
        • Chambless L.E.
        • Liao D.
        • Prineas R.J.
        • Evans G.W.
        • Rosamond W.D.
        • Heiss G.
        Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study.
        Diabetes Care. 2005; 28: 668-674
        • Bucchi A.
        • Baruscotti M.
        • Robinson R.B.
        • DiFrancesco D.
        Modulation of rate by autonomic agonists in SAN cells involves changes in diastolic depolarization and the pacemaker current.
        J Mol Cell Cardiol. 2007; 43: 39-48
        • Carnethon M.R.
        • Yan L.
        • Greenland P.
        • Garside D.B.
        • Dyer A.R.
        • Metzger B.
        • Daviglus M.L.
        Resting heart rate in middle age and diabetes development in older age.
        Diabetes Care. 2008; 31: 335-339
        • Ranjadayalan K.
        • Umachandran V.
        • Ambepityia G.
        • Kopelman P.G.
        • Mills P.G.
        • Timmis A.D.
        Prolonged anginal perceptual threshold in diabetes: effects on exercise capacity and myocardial ischemia.
        J Am Coll Cardiol. 1990; 16: 1120-1124
        • Daly C.A.
        • De Stavola B.
        • Lopez Sendon J.L.
        • Tavazzi L.
        • Boersma E.
        • Clemens F.
        • Danchin N.
        • Delahaye F.
        • Gitt A.
        • Julian D.
        • Mulcahy D.
        • Ruzyllo W.
        • Thygesen K.
        • Verheugt F.
        • Fox K.M.
        Predicting prognosis in stable angina—results from the Euro heart survey of stable angina: prospective observational study.
        BMJ. 2006; 332: 262-267
        • Izzedine H.
        • Launay-Vacher V.
        • Deybach C.
        • Bourry E.
        • Barrou B.
        • Deray G.
        Drug-induced diabetes mellitus.
        Expert Opin Drug Saf. 2005; 4: 1097-1109
        • Blackburn D.F.
        • Wilson T.W.
        Antihypertensive medications and blood sugar: theories and implications.
        Can J Cardiol. 2006; 22: 229-233
        • Barzilay J.I.
        • Davis B.R.
        • Cutler J.A.
        • Pressel S.L.
        • Whelton P.K.
        • Basile J.
        • Margolis K.L.
        • Ong S.T.
        • Sadler L.S.
        • Summerson J.
        Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
        Arch Intern Med. 2006; 166: 2191-2201
        • Gress T.W.
        • Nieto F.J.
        • Shahar E.
        • Wofford M.R.
        • Brancatti F.L.
        Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: Atherosclerosis Risk in Communities Study.
        N Engl J Med. 2000; 342: 905-912
        • Dahlof B.
        • Sever P.S.
        • Poulter N.R.
        • Wedel H.
        • Beevers D.G.
        • Caulfield M.
        • Collins R.
        • Kjeldsen S.E.
        • Kristinsson S.
        • McInnes G.T.
        • Mehlsen J.
        • Nieminen M.
        • O'Brien E.
        • Ostergren J.
        Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
        Lancet. 2005; 366: 895-906
        • Pollare T.
        • Lithell H.
        • Selinus I.
        • Berne C.
        Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.
        BMJ. 1989; 298: 1152-1157
        • Ostman J.
        • Asplund K.
        • Bystedt T.
        • Dahlof B.
        • Jern S.
        • Kjellstrom T.
        • Lithell H.
        • Swedish Quinapril Group
        Comparison of effects of quinapril and metoprolol on glycaemic control, serum lipids, blood pressure, albuminuria and quality of life in non-insulin-dependent diabetes mellitus patients with hypertension.
        J Intern Med. 1998; 244: 95-107
        • Bakris G.L.
        • Fonseca V.
        • Katholi R.E.
        • McGill J.B.
        • Messerli F.H.
        • Phillips R.A.
        • Raskin P.
        • Wright Jr, J.T.
        • Oakes R.
        • Lukas M.A.
        • Anderson K.M.
        • Bell D.S.
        Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
        JAMA. 2004; 292: 2227-2236
        • Gibbons R.J.
        • Abrams J.
        • Chatterjee K.
        • Daley J.
        • Deedwania P.C.
        • Douglas J.S.
        • Ferguson Jr, T.B.
        • Fihn S.D.
        • Fraker Jr, T.D.
        • Gardin J.M.
        • O'Rourke R.A.
        • Pasternak R.C.
        • Williams S.V.
        ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina).
        (Accessed February, 2008)
        • Carasso S.
        • Markiewicz W.
        Medical treatment of patients with stable angina pectoris referred for coronary angiography: failure of treatment or failure to treat.
        Clin Cardiol. 2002; 25: 436-441